Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019

• DOI: 10.1093/infdis/jiaa505
• Publication Date: 2020-08-05T11:12:10Z
• Authors: Steven B Bradfute; Ivy Hurwitz; Alexandra V Yingling; Chunyan Ye; Qiuying Cheng; Timothy P Noonan; Jay S Raval; Nestor R Sosa; Gregory J Mertz; Douglas J Perkins; Michelle S Harkins
• Keywords: Convalescent plasma; Coronavirus; Antibody titer

Convalescent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers in donor and their impact patients with acute COVID-19 remains largely undetermined. We measured NAb CP before after transfusion through the traditional Food Drug Administration investigational new drug pathway.We performed single-arm interventional trial measuring total over 14-day period hospitalized laboratory-confirmed severe respiratory syndrome 2 infection.NAb units were low (<1:40 to 1:160) had no effect on recipient activity 1 day transfusion. detected 6 of 12 enrollment 11 at ≥2 time points. Average peaked 7 declined toward 14 (P = .004). Nab immunoglobulin G levels correlated (ρ 0.938; P < .001) cumulative patient measures 0.781; .001).CP infusion did not alter titers. Prescreening may be necessary selecting donors high into COVID-19.NCT04434131.